

#### REMARKS

Reconsideration and allowance are respectfully requested.

Claims 1 to 28 have been canceled. Minor amendments have been made to claims 29 to 32 for clarity and to correct grammar. No new matter is added by the present amendments to the claims.


The Examiner rejected claims 1 to 39 for obviousness over Hieble, Ukimura, and the combination of Hieble and Ukimura. Claims 1 to 28 have been canceled, and the rejections as to those claims are moot and should be withdrawn.

Subsisting claims 29 to 39 are claims directed to methods for the treatment of lower urinary tract symptoms associated with benign prostate hyperplasia. Ukimura discloses absolutely nothing about benign prostate hyperplasia or its symptoms, much less the treatment of such symptoms, and so it is respectfully submitted that Ukimura by itself cannot properly be said to suggest treating the symptoms associated with benign prostate hyperplasia, and so it is respectfully requested that the rejection of claims 29 to 39 as obvious over Ukimura alone be withdrawn.

It is respectfully submitted that Hieble directly and specifically teaches away from the methods of the present claims. On page 287s, lines 3 to 5, Hieble unequivocally states that muscarinic antagonists should NOT be used in patients with outlet obstruction because contractions of the bladder are inhibited by muscarinic antagonists, and so such patients may therefore suffer from urinary retention if administered muscarinic antagonists. The essence of benign prostate hyperplasia is outlet obstruction. Thus, Hieble teaches NOT to give a muscarinic antagonist to a benign prostate hyperplasia sufferer, directly contrary to the requirements of the present claims. In light of this teaching, it is respectfully submitted that a rejection of the present claims based on the disclosure of Hieble, alone or in combination with another reference, is untenable, and the rejection of claims 29 to 39 should be withdrawn.

In light of the above remarks and amendments, it is respectfully submitted that claims 29 to 39 are in condition for allowance, and such action is earnestly solicited.

Respectfully submitted, \



David E. Wildman  
Attorney for Applicant  
Reg. No. 40,226

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(862) 778-7954  
Date: January 28, 2003